aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Orbital Therapeutics is dedicated to advancing global health by harnessing the potential of RNA-based medicines to treat human diseases in novel ways. The company focuses on developing innovative RNA therapies that address unmet medical needs, aiming to revolutionize the treatment landscape.
Orbital Therapeutics has achieved significant milestones in RNA medicine development, contributing to the broader acceptance and application of RNA-based therapies. Their work has positioned them as a key player in the biotech industry, driving forward the capabilities of RNA technology in healthcare.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Medicines, RNA Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
Global
When was Orbital Therapeutics founded?
Orbital Therapeutics was founded in 2022.
Where is Orbital Therapeutics’s headquarters located?
Orbital Therapeutics’s headquarters is located in Cambridge, MA, US.
When was Orbital Therapeutics’s last funding round?
Orbital Therapeutics’s most recent funding round was for $270M (USD) in April 2023.
How many employees does Orbital Therapeutics have?
Orbital Therapeutics has 33 employees as of Feb 5, 2024.
How much has Orbital Therapeutics raised to-date?
As of July 05, 2023, Orbital Therapeutics has raised a total of $270M (USD) since Apr 26, 2023.
Add Comparison
Total Raised to Date
$270M
USD
Last Update Apr 26, 2023
Last Deal Details
$270M
USD
Apr 26, 2023
Series A
Total Employees Over Time
33
As of Feb 2024
Orbital Therapeutics Address
21 Erie St
Cambridge,
Massachusetts
02139
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts